Tirzepatide SURMOUNT-1 (2022) and SURPASS-2 (2021) SURMOUNT-1 (Jastreboff et al., NEJM 2022): 2,539 non-diabetic adults with BMI 30, 72 weeks of tirzepatide 15 mg/week: Weight loss: 20.9% (vs 3.1% placebo) 91% of participants 5% loss, 56.7% 20% SURPASS-2 (Fras et al., NEJM 2021): 1,879 T2D patients head-to-head vs semaglutide 1 mg: HbA1c: 2.30% (tirzepatide 15 mg) vs 1.86% (semaglutide) Weight loss: 11.2 kg vs 5.7 kg Tirzepatide statistically outperforms semaglutide on both HbA1c and weight in a head-to-head trial a rare outcome in incretin pharmacology
The aim is steady progress you can maintain, guided by our founder and lead provider, Alina McCann, MSN, APRN, AGNP
Important Information About IV Therapy
In transected muscle models, the peptide accelerates myofiber bridging by promoting satellite cell activation and fusion, reducing scar tissue formation by 4060%
The study compared equivalent 12-week courses of the drugs and found that tirzepatide causes 10.96kg of weight loss at the highest once-weekly 15mg dose, compared to 5.24kg for Wegovy
Results 1215% body weight reduction over 612 months (with lifestyle support) 510% body weight reduction over several months Cost Program-based pricing (medication, labs, supervision) Typically lower upfront, varies by brand and insurance Formulations GLP-1 receptor agonists (e.g., semaglutide) Appetite suppressants, fat blockers, or stimulants Timeline Noticeable appetite suppression within 12 weeks
